ArticleThe oncologist2026

Toxicity Attribution During Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Practical Framework.

Jabra Zarka et al.PubMed ↗Publisher ↗

No numbers read from the abstract.